ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Biologic agents"

  • Abstract Number: 053 • 2023 Pediatric Rheumatology Symposium

    Can Children with Colchicine Resistant FMF Be Treated with on Demand Canakinumab Regimen?– a Multicenter Study

    Katy shehadeh1, Yoel Levinsky2, rotem tal3, Neta Hana Aviran3, Yonatan Butbul Aviel4, Irit Tirosh5, Shelly Kagan6, Tarek Zoabi3, Shiri Spielman7, Adi Miller-Barmak4, Rotem Semo Oz8, Liora Harel9, Gabriel Chodick10 and Gil Amarilyo6, 1Tel Aviv University, Tel Aviv, Israel, 2Schneider Children's Medical Center of Israel, Tel Aviv University, Petach Tikva, Israel, 3Schneider Children's Medical Center of Israel, Petach Tikva, Israel, 4Rambam Medical center, Haifa, Israel, 5Sheba Medical Center, Savyon, Israel, 6Schneider Children's Medical Center of Israel, Petach Tikva, Israel, 7Sheba Tel-HaShomer Medical Center, Givataim, Israel, 8Sheba medical center, Herzelyia, Israel, 9Scheiders Children Medical Center of Israel, Petah-Tiqva, Israel, 10Maccabitech institute for research and innovation, Maccabi healthcare services, Tel Aviv, Israel

    Background/Purpose: Familial Mediterranean fever (FMF) is the most common autoinflammatory disease. Without therapy, it may lead to the development of secondary amyloidosis. Treatment with colchicine…
  • Abstract Number: 036 • 2020 Pediatric Rheumatology Symposium

    Medication Related Decision-Making in Parents of Children with Juvenile Idiopathic Arthritis

    Alexandra Munroe1, Adam Huber 2, Bianca Lang 3, Suzanne Ramsey 4 and Elizabeth Stringer 4, 1Dalhousie University, Halifax, Nova Scotia, Canada, 2IWK Health Centre & Dalhousie University, Halifax, Nova Scotia, Canada, 3Dalhousie University - Halifax, Halifax, Canada, 4IWK Health Centre, Halifax, Canada

    Background/Purpose: Outcomes for juvenile idiopathic arthritis (JIA) have improved with use of disease-modifying anti-rheumatic drugs (DMARDs) and biologics. Despite this, the decision by a parent…
  • Abstract Number: 092 • 2020 Pediatric Rheumatology Symposium

    The Initial Treatment of Systemic Juvenile Idiopathic Arthritis: An International Collaboration Among 10 Registries

    Mary Beth Son1, Yukiko Kimura 2, Kristiina Aalto 3, Lillemor Berntson 4, Johnathan Dallas 1, Ciaran Duffy 5, Mia Glerup 6, Jaime Guzman 7, Troels Herlin 8, Petteri Hovi 9, Kimme Hyrich 10, Jens Klotsche 11, Bo Magnusson 12, Vanessa McIntyre 13, Ellen Nordal 14, Seza Ozen 15, Maria Jose Santos 16, Betul Sozeri 17 and Timothy Beukelman 18, 1Boston Children's Hospital, Boston, Massachusetts, 2Hackensack Meridian School of Medicine, Hackensack, 3Department of Pediatrics, New Children's Hospital, Helsinki University Hospital, Pediatric Research Center, University of Helsinki, Helsinki, Finland., HUS, Finland, 4Department of Womens and Childrens Health, Uppsala University, Uppsala, Sweden., Uppsala, Sweden, 5Ottawa, Canada, 6Department of Pediatrics, Aarhus University Hospital, Aarhus, Denmark, Aarhus, Denmark, 7University of British Columbia and BC Children's Hospital, Vancouver, Canada, 8Department of Pediatrics, Aarhus University Hospital, Aarhus, Denmark., Aarhus N, Denmark, 9Helsinki University Hospital, Helsinki, Finland, 10Manchester, United Kingdom, 11Berlin, Germany, 12Karolinska University Hospital, Stockholm, Sweden, 13Manchester University, Manchester UK, United Kingdom, 14Department of Pediatrics, University Hospital of North Norway, and Department of Clinical Medicine, UiT The Arctic University of Norway, Tromsø, Norway., Tromsø, Norway, 15Hacettepe University, Division of Pediatric Rheumatology, Department of Pediatrics, Faculty of Medicine, 16Portugal, 17Boston, Turkey, 18University of Alabama at Birmingham, Birmingham

    Background/Purpose: The introduction of biologic medications has revolutionized the care of children with systemic juvenile idiopathic arthritis (SJIA). Differences in treatment approaches among different countries…
  • Abstract Number: 137 • 2020 Pediatric Rheumatology Symposium

    Measuring Decision Conflict in Parents of Children with Juvenile Idiopathic Arthritis When Making the Decision to Begin Disease Modifying Anti-Rheumatic Drugs or Biologic Agents

    Chelsea DeCoste1, Suzanne Ramsey 2, Adam Huber 3, Bianca Lang 4 and Elizabeth Stringer 2, 1The Hospital for Sick Children, Toronto, Canada, 2IWK Health Centre, Halifax, Canada, 3IWK Health Centre & Dalhousie University, Halifax, Nova Scotia, Canada, 4Dalhousie University - Halifax, Halifax, Canada

    Background/Purpose: Disease-modifying antirheumatic drugs (DMARDs) and biologic agents are routinely used in the treatment of JIA and JIA-associated uveitis (JIA-AU). Parents are often fearful, however,…
  • Abstract Number: L19 • 2019 ACR/ARP Annual Meeting

    Ianalumab (VAY736), a Dual Mode of Action Biologic Combining BAFF Receptor Inhibition with B Cell Depletion, for Treatment of Primary Sjögren’s Syndrome: Results of an International Randomized, Placebo Controlled Dose Range Finding Study in 190 Patients

    Simon Bowman1, Robert Fox 2, Thomas Dörner 3, Xavier Mariette 4, Athena Papas 5, Thomas Grader-Beck 6, Benjamin A. Fisher 7, Filipe Barcelos 8, Salvatore De Vita 9, Hendrik Schulze-Koops 10, Robert J. Moots 11, Guido Junge 12, Janice Woznicki 13, Monika Sopala 12, Wen-Lin Luo 13 and Wolfgang Hueber 12, 1University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom, 2Scripps Memorial Hospital and Research Institute, La Jolla, California, 3Charite Universitätsmedizin Berlin and DRFZ, Berlin, Germany, 4Center for Immunology of Viral Infections and Autoimmune Diseases, Assistance Publique – Hôpitaux de Paris, Hôpitaux Universitaires Paris-Sud, Le Kremlin-Bicêtre, Université Paris Sud, INSERM, Paris, France, 5Tufts School of Dental Medicine, Massachusetts, 6Johns Hopkins University, Baltimore, 7University Hospitals Birmingham NHS Foundation Trust, Birmingham Biomedical Research Centre, Birmingham, United Kingdom, 8Nova Medical School, Hospital Cuf Descobertas, Instituto Português de Reumatologia,, Lisbon, Portugal, 9Rheumatology Clinic, Udine University Hospital, Department of Medical Area, University of Udine, Udine, Italy, Udine, Italy, 10Department of Rheumatology/Clinical Immunology, Ludwig-Maximilians-University Munich, Munich, Germany, 11Institute of Ageing and Chronic Disease, Liverpool, United Kingdom, 12Novartis Pharma AG, basel, Switzerland, 13Novartis Pharmaceuticals Corporation, New Jersey

    Background/Purpose: Primary Sjogren’s syndrome (pSS) is a multi-organ autoimmune disease primarily affecting excretory glands and characterized by B-cell hyperactivity. No approved systemic treatments are available.…
  • Abstract Number: 1389 • 2019 ACR/ARP Annual Meeting

    Treatment Response to Biologic DMARDs in Patients with RA: A Retrospective Analysis of the RISE Registry

    Xue Han1, Joshua Bryson 1, David C Crosby 1, Michael Evans 2 and Gabriela Schmajuk 3, 1Bristol-Myers Squibb, Princeton, 2University of California San Francisco, San Francisco, 3UCSF, SFVAMC Division of Rheumatology, San Francisco, CA

    Background/Purpose: ACR guidelines recommend treatment for patients with RA based on baseline (BL) disease activity. In patients with an inadequate response to conventional synthetic DMARDs,…
  • Abstract Number: 1437 • 2019 ACR/ARP Annual Meeting

    Comparison of the Efficacy and Safety of Abatacept in Rheumatoid Arthritis Patients with and Without Interstitial Lung Disease

    Sho Sasaki1, Akira Ishii 2, Mai Sugiyama 2, Yuto Izumi 2, Yoko Nakagome 2, Kazuki Hirano 3, Takayoshi Kurabayashi 1, Noriko Sasaki 2, Chiho Yamada 2 and Shinji Sato 4, 1Tokai Universitiy School of Medicine, Isehara, Japan, 2Tokai University School of Medicine, Isehara, Japan, 3Tokai University School of Medicine, Isehara, 4Division of Rheumatology, Department of Internal Medicine, Tokai University School of Medicine, Yokohama, Japan

    Background/Purpose: Interstitial lung disease (ILD) is one of complication in patients with rheumatoid arthritis (RA) and its presence often has an effect on the management…
  • Abstract Number: 1496 • 2019 ACR/ARP Annual Meeting

    Comparative Effectiveness of Ustekinumab and TNF Inhibitors in Patients with Psoriatic Arthritis in a Real-world, Multicenter Study

    Josef Smolen1, Panagiotis Athanassiou 2, Paul Bergmans 3, Irina Bondareva 4, Kurt De Vlam 5, Elisa Gremese 6, Beatriz Joven-Ibáñez 7, Tatiana Korotaeva 8, Wim Noël 9, Michael Nurmohamed 10, Petros Sfikakis 11, Stefan Siebert 12, Pavel Smirnov 13, Elke Theander 14 and Laure Gossec 15, 1Medical University of Vienna, Vienna, Austria, 2General Hospital of Thessaloniki “Agios Pavlos”, Thessaloniki, Greece, 3Biostatistics and Medical Affairs, Janssen, Tilburg, Netherlands, 4GUZ Kemerovo Regional Clinical Hospital, Kemerovo, Russia, 5University Hospitals Leuven, Leuven, Belgium, 6Fondazione Policlinico Gemelli-Università Cattolica del Sacro Cuore, Rome, Italy, 7Hospital Universitario 12 de Octubre, Madrid, Spain, 8Nasonova Research Institute of Rheumatology, Moscow, Russia, 9Biostatistics and Medical Affairs, Janssen, Brussels, Belgium, 10Reade and VU Rheumatology Research Department, Amsterdam, Netherlands, 11Joint Rheumatology Programme, National & Kapodistrian University of Athens Medical School, Athens, Greece, Athens, Greece, 12Institute of Infection, Immunity & Inflammation, University of Glasgow, Glasgow, United Kingdom, 13Biostatistics and Medical Affairs, Janssen, Moscow, Russia, 14Biostatistics and Medical Affairs, Janssen, Solna, Sweden, 15Sorbonne Université and Hôpital Pitié-Salpêtrière, Paris, France

    Background/Purpose: Among the treatment options for PsA, IL-12/23 inhibition with ustekinumab (UST) was the first new biologic mode of action after TNF inhibitors (TNFi). Few…
  • Abstract Number: 1500 • 2019 ACR/ARP Annual Meeting

    Effectiveness of Switching Between TNF Inhibitors in Patients with Axial Spondyloarthritis: Is the Reason to Switch Relevant?

    Santiago Rodrigues-Manica1, Alexandre Sepriano 2, Fernando Pimentel-Santos 1, Nélia Gouveia 3, Anabela Barcelos 4, Jaime Branco 1, Miguel Bernardes 5, Raquel Miriam-Ferreira 5, Elsa Vieira-Sousa 6, Sofia Barreira 6, Filipe Vinagre 7, Raquel Roque 7, Helena Santos 8, Nathalie Madeira 8, João Rovisco 9, Alexandra Daniel 9 and Sofia Ramiro 10, 1CEDOC, NOVA-Medical School | Hospital Egas Moniz, CHLO, Lisbon, Lisbon, Portugal, 2Leiden University Medical Center, Leiden, Netherlands, 3CEDOC, NOVA-Medical School, Lisbon, Portugal, Lisboa, Portugal, 4Centro Hospitalar Baixo Vouga | iBemed, University of Aveiro, Aveiro, Portugal, 5Rheumatology, Centro Hospitalar de São João, Porto, Portugal, Porto, Portugal, 6Rheumatology and Metabolic Bone Diseases, Hospital de Santa Maria - Centro Hospitalar Lisboa Norte, EPE | Rheumatology Research Unit, Instituto de Medicina Molecular - Faculty of Medicine, University of Lisbon, Lisbon Academic Medical Centre, Lisbon, Portugal,, Lisbon, Portugal, 7Rheumatology, Hospital Garcia de Orta, Almada, Portugal, Almada, Portugal, 8Instituto Português de Reumatologia (IPR), Lisbon, Portugal, 9Rheumatology, Centro Hospitalar e Universitário de Coimbra, Coimbra, Coimbra, Portugal, 10Leiden University Medical Center and Zuyderland Medical Centre, Leiden, Netherlands

    Background/Purpose: Over the last years, and mostly due to lack of alternatives, it has been common practice to start a second TNF inhibitor (TNFi) in…
  • Abstract Number: 1519 • 2019 ACR/ARP Annual Meeting

    Predicting Response to Biologic Therapy in Patients with Axial Spondyloarthritis (axSpA)

    Gareth Jones1, Linda Dean 1, Ejaz Pathan 2 and Gary Macfarlane 1, 1University of Aberdeen, Aberdeen, United Kingdom, 2Toronto Western Hospital, Toronto, Canada

    Background/Purpose: In axial spondyloarthritis (axSpA), the clinical benefits of TNF inhibition (TNFi) are well documented although, by design, most studies report average benefits in groups…
  • Abstract Number: 1751 • 2019 ACR/ARP Annual Meeting

    A Systematic Literature Review of Efficacy and Safety of Biologic Agents for the Treatment of Juvenile Dermatomyositis

    edoardo marrani1, Sarah Abu Rumeileh 1, Francesca Tirelli 2, Ilaria Maccora 3 and Gabriele Simonini 4, 1Post graduate School of pediatrics, University of Florence, Firenze, Italy, 2Post Graduate School of Pediatrics, University of Florence, Florence, Italy, Firenze, Italy, 3Post Graduate School of Pediatrics, University of Florence, Florence, Italy, Florence, Toscana, Italy, 4Anna Meyer Children's Hospital, Flotence, Italy

    Background/Purpose: Juvenile dermatomyositis (JDM) is a rare, chronic autoimmune illness characterized by symmetric, proximal muscle damages and involvement of the skin. While first line treatment…
  • Abstract Number: 1802 • 2019 ACR/ARP Annual Meeting

    Utility of Repeat Latent Tuberculosis Testing in Patients Taking Biologics

    Urmi Khanna1, Ariana Ellis 2, AbdulAziz Galadari 3, Jeffery Hu 4, Josh Gallop 5, M. Elaine Husni 6 and Anthony Fernandez 7, 1Department of Dermatology , Cleveland Clinic, Cleveland, OH, 2Northeast Ohio Medical University, Cleveland, OH, 3Cleveland Clinic, Abu Dhabi, Cleveland, 4Case Western Reserve University, Cleveland, 5Cleveland Clinic Lerner College of Medicine, Cleveland, OH, 6Department of Rheumatologic and Immunologic Diseases, Cleveland Clinic, Cleveland, OH, 7Department of Dermatology and Pathology, Cleveland Clinic, Cleveland, OH

    Background/Purpose: Guidelines for repeat Latent Tuberculosis Infection (LTBI) testing while on biologics are not clearly defined. The American College of Rheumatology recommends repeat LTBI screening…
  • Abstract Number: 1822 • 2019 ACR/ARP Annual Meeting

    6 and 12-month Drug Retention Rates and Treatment Outcomes in 941 Patients with Axial Spondyloarthritis Treated with Secukinumab in Routine Clinical Practice in 12 European Countries in the EuroSpA Research Collaboration Network

    Brigitte Michelsen1, Johan Askling 2, Catalin Codreanu 3, Herman Mann 4, Anne Gitte Loft 5, Manuel Pombo-Suarez 6, Ziga Rotar 7, Tore Kvien 8, Maria José Santos 9, Anna Mari Hokkanen 10, Florenzo Iannone 11, Bjorn Gudbjornsson 12, Fatos Onen 13, Lennart Jacobsson 14, Ruxandra IONESCU 15, Karel Pavelka 4, Carlos Sánchez-Piedra 16, Matija Tomsic 17, Joe Sexton 18, Helena Santos 19, Jenny Österlund 20, Alberto Cauli 21, Arni Jon Geirsson 22, Servet Akar 23, Adrian Ciurea 24, Gareth Jones 25, Irene van der Horst-Bruinsma 26, Cecilie Heegaard Brahe 27, Stylianos Georgiadis 28, Lykke Midtbøll Ørnbjerg 27, Mikkel Østergaard 29 and Merete Lund Hetland 30, 1Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet Glostrup, Denmark/ Hospital of Southern Norway Trust, Kristiansand, Norway/ Diakonhjemmet Hospital, Oslo, Norway, Oslo, Norway, 2Karolinska Institutet, Stockholm, Sweden, 3Center of Rheumatic Diseases, University of Medicine and Pharmacy, Bucharest, Romania., Bucharest, Romania, 4Institute of Rheumatology, Department of Rheumatology, 1st Faculty of Medicine, Prague, Czech Republic, Prague 2, Czech Republic, 5Department of Rheumatology, Aarhus University Hospital, Aarhus, Denmark, Århus, Denmark, 6Unit Research, Spanish Society of Rheumatology, Madrid, Spain, 7UMC LJUBLJANA, DPT. OF RHEUMATOLOGY, LJUBLJANA, Slovenia, 8Diakonhjemmet Hospital, Dept. of Rheumatology / University of Oslo, Faculty of Medicine, Oslo, Norway, 9Rheumatology department, Hospital Garcia de Orta, Almada, Portugal, 10Helsinki University Hospital, Helsinki, Finland, 11Department of Emergency and Transplantation , Rheumatology Unit, University Hospital of Bari, Bari, Italy., Bari, Italy, 12Centre for Rheumatology Research, Landspitali and Faculty of Medicine, University of Iceland, Reykjavik, Iceland, 13Dokuz Eylul University School of Medicine, Division of Rheumatology, İzmir, Turkey, 14Dept of Rheumatology and Inflammation Research, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Sweden,, Gothenburg, Sweden, 15SPITALUL CLINIC SFANTA MARIA, Bucharest, 16Research Unit, Spanish Society of Rheumatology, Madrid, Spain, 17Department of Rheumatology, University Medical Center Ljubljana, Slovenia, Ljubljana, Slovenia, 18Diakonhjemmet Hospital, Dept. of Rheumatology, Oslo, Norway, 19Instituto Português de Reumatologia (IPR), Lisbon, Portugal, 20ROB-FIN registry, Helsinki University and Helsinki University Hospital, Helsinki, Finland, 21Universitá di Cagliari, Cagliari, Italy, 22Centre for Rheumatology Research, University Hospital and Faculty of Medicine, Reykjavik, Iceland, 23Izmir Katip Celebi University, Faculty of Medicine, Division of Rheumatology, İzmir, Turkey, 24University Hospital Zürich, Zürich, Switzerland, 25University of Aberdeen, Aberdeen, United Kingdom, 26Amsterdam University Medical Center, Amsterdam, Netherlands, 27Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet Glostrup, Denmark, Copenhagen, Denmark, 28DANBIO registry and Copenhagen Center for Arthritis Research, Centre for Rheumatology and Spine Diseases, Rigshospitalet, Copenhagen, Denmark, 29Copenhagen Center for Arthritis Research, University of Copenhagen, Copenhagen, Denmark, 30DANBIO and Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Centre of Head and Orthopaedics, Rigshospitalet, Copenhagen, Denmark

    Background/Purpose: Secukinumab is a fully human IgG1 monoclonal antibody targeting interleukin-17A. There is a lack of real-life evidence on secukinumab retention rates and treatment outcomes…
  • Abstract Number: 2099 • 2019 ACR/ARP Annual Meeting

    Comparison of Single and Dual Latent Tuberculosis Screening Strategies Before the Initiation of Biologic and Targeted Therapy in Rheumatological Patients in Hong Kong

    Yan Ki Tang1, Ho So 2, Weng Nga Virginia Lao 2, Hin Ting Pang 2, Tak Lung Victor Wong 2, Tsz Ho Luk 2 and Man Lung Ronald Yip 3, 1Department of Medicine and Geriatrics, Kwong Wah Hospital, Hong Kong, Hong Kong, 2Department of Medicine & geriatrics, Kwong Wah Hospital, Hong Kong, Hong Kong, 3Tung Wah Group of Hospitals Integrated Diagnostic and Medical Centre, Hong Kong, Hong Kong

    Background/Purpose: Screening for latent tuberculosis infection (LTBI) before the initiation of biologic and targeted synthetic disease modifying anti-rheumatic drugs (b/tsDMARDs) is recommended internationally especially in…
  • Abstract Number: 2131 • 2019 ACR/ARP Annual Meeting

    Rituximab Safety and Persistence in Patients with Systemic Autoimmune Diseases

    Cristóbal Pavez Perales1, Jorge Juan Fragio Gil 1, Roxana Gonzalez Mazarío 1, José Ivorra Cortés 1, Elena Grau García 1, Cristina Alcañiz Escandell 1, Inmaculada Chalmeta Verdejo 1, Marta de la Rubia Navarro 1, Luis González Puig 1, Isabel Martínez Cordellat 1, Rosa Negueroles Albuixech 1, José Eloy Oller Rodríguez 2, Francisco Miguel Ortiz-Sanjuán 1, Elvira Vicens Bernabeu 1, Carmen Nájera Herranz 1, Inés Cánovas Olmos 1, Samuel Leal Rodriguez 1 and José Andrés Román Ivorra 1, 1Rheumatology Department. HUP La Fe, Valencia, Comunidad Valenciana, Spain, 2Rheumatology Department. HUP La Fe, v, Comunidad Valenciana, Spain

    Background/Purpose: Rituximab (RTX), an anti-CD20 monoclonal antibody inducing B cell depletion, is used as therapy for diverse systemic autoimmune diseases (SAIDs), but is associated with adverse events…
  • 1
  • 2
  • 3
  • …
  • 26
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology